Structural and functional alterations of the heart in Parkinson’s disease

References

• Pringsheim T, Jette N, Frolkis A, et al. The prevalence of Parkinson’s disease: A systematic review and meta-analysis. Mov Disord. 2014;29:1583–1590.10.1002/mds.v29.13
   PubMed Web of Science ®Google Scholar
• Bui AL, Horwich T, Fonarow GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol. 2011;8:30–41.10.1038/nrcardio.2010.165
   PubMed Web of Science ®Google Scholar
• Zesiewicz T, Strom J, Borenstein A, et al. Heart failure in Parkinson’s disease: analysis of the United States medicare current beneficiary survey. Park Relat Disord. 2004;10:417–420.10.1016/j.parkreldis.2004.04.001
   PubMed Web of Science ®Google Scholar
• Pennington S, Snell K, Lee M, et al. The cause of death in idiopathic Parkinson’s disease. Parkinsonism Relat Disord. 2010;16:434–437. DOI:10.1016/j.parkreldis.2010.04.010.
   PubMed Web of Science ®Google Scholar
• Fernandez HH, Lapane KL. Predictors of mortality among nursing home residents with a diagnosis of Parkinson’s disease. Med Sci Monit. 2002;8:241–246.
   Google Scholar
• Liang HWMD, Pan SL, Haung YP. Parkinson disease and risk of acute myocardial infarction: a population-based, propensityscore–matched, longitudinal follow-up study. Am Heart J. 2015;169:508–514.10.1016/j.ahj.2014.11.018
   PubMed Web of Science ®Google Scholar
• Zanettini R, Antonini A, Gatto G, et al. Valvular heart disease and the use of dopamine agonists for parkinson’s disease. N Engl J Med. 2007;356:39–46.10.1056/NEJMoa054830
   PubMed Web of Science ®Google Scholar
• Tran T, Brophy JM, Suissa S, et al. Risks of cardiac valve regurgitation and heart failure associated with ergot- and non-ergot-derived dopamine agonist use in patients with parkinson’s disease: a systematic review of observational studies. CNS Drugs. 2015;29:985–998.10.1007/s40263-015-0293-4
   PubMed Web of Science ®Google Scholar
• Chen Y, Dorn G. PINK1-Phosphorylated mitofusin 2 is a Parkin receptor for culling damaged mitochondria. Science. 2013;340:471–475.10.1126/science.1231031
   PubMed Web of Science ®Google Scholar
• Mukherjee UA, Ong S-B, Ong S-G, et al. Parkinson’s disease proteins: Novel mitochondrial targets for cardioprotection. Pharmacol Ther. 2015;156:34–43. DOI:10.1016/j.pharmthera.2015.10.005.
   PubMed Web of Science ®Google Scholar
• Goldstein DS. Dysautonomia in Parkinson disease. Compr Physiol. 2014;4:805–826.
   PubMed Web of Science ®Google Scholar
• Velseboer DC, de-Haan RJ, Wieling W, et al. Prevalence of orthostatic hypotension in Parkinson’s disease: A systematic review and meta-analysis. Park Relat Disord. 2011;17:724–729.10.1016/j.parkreldis.2011.04.016
   PubMed Web of Science ®Google Scholar
• Li S, Dendi R, Holmes C, et al. Progressive loss of cardiac sympathetic innervation in Parkinson’s disease. Ann Neurol. 2002;52:220–223.10.1002/(ISSN)1531-8249
   PubMed Web of Science ®Google Scholar
• Fanciulli A, Gobel G, Ndayisaba JP, et al. Supine hypertension in Parkinson’s disease and multiple system atrophy. Clin Auton Res. 2016;26:97–105. DOI:10.1007/s10286-015-0336-4.
   PubMed Web of Science ®Google Scholar
• Umehara T, Toyoda C, Oka H. Postprandial hypotension in de novo Parkinson’s disease: a comparison with orthostatic hypotension. Parkinsonism Relat Disord. 2014;20:573–577. DOI:10.1016/j.parkreldis.2014.02.007.
   PubMed Web of Science ®Google Scholar
• Kanegusuku H, Silva-Batista C, Peçanha T, et al. Patients with Parkinson disease present high ambulatory blood pressure variability. Clin Physiol Funct Imag. 2016;37(5):530–535. DOI:10.1111/cpf.12338.
   PubMed Web of Science ®Google Scholar
• Solla P, Cannas A, Deidda M, et al. Heart rate variability shows different cardiovascular modulation in Parkinson’s disease patients with tremor dominant subtype compared to those with akinetic rigid dominant subtype. J Neural Transm. 2015;122(10):1441–1446. DOI:10.1007/s00702-015-1393-5.
   PubMed Web of Science ®Google Scholar
• Palma J-A, Kaufmann H. Autonomic disorders predicting Parkinson disease. Parkinsonism Relat Disord. 2014;20(1):S94–S98. DOI:10.1016/S1353-8020(13)70024-5.
   PubMedGoogle Scholar
• Orimo S, Uchihara T, Nakamura A, et al. Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson’s disease. Brain. 2008;131:642–650. DOI:10.1093/brain/awm302.
   PubMed Web of Science ®Google Scholar
• Shibata M, Morita Y, Shimizu T, et al. Cardiac parasympathetic dysfunction concurrent with cardiac sympathetic denervation in Parkinson’s disease. J Neurol Sci. 2009;276:79–83. DOI:10.1016/j.jns.2008.09.005.
   PubMed Web of Science ®Google Scholar
• Gelpi E, Navarro-Otano J, Tolosa E, et al. Multiple organ involvement by alpha-synuclein pathology in Lewy body disorders. Mov Disord. 2014;29:1010–1018. DOI:10.1002/mds.25776.
   PubMed Web of Science ®Google Scholar
• Wakabayashi K, Takahashi H. Neuropathology of autonomic nervous system in Parkinson’s disease. Eur Neurol. 1997; 38:2e7.
   Web of Science ®Google Scholar
• Postuma R, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015;30:1591–1601.10.1002/mds.26424
   PubMed Web of Science ®Google Scholar
• The Criteria Committee of the New York Heart Association Nomenclature and criteria for diagnosis of diseases of the heart and blood vessels. Boston: Little Brown; 1964.
   Google Scholar
• Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology. 1967;17:427–427.10.1212/WNL.17.5.427
   PubMed Web of Science ®Google Scholar
• Fahn S, Elton R. Members of the UPDRS Development Committee. Unified Parkinson’s Disease Rating Scale. Recent Dev Park Dis. 1987.
   Google Scholar
• Romenets S, Wolfson C, Galatas C, et al. Validation of the non-motor symptons questionnaire (NMS-Quest). Park Relat Disord. 2012;18:54–58.10.1016/j.parkreldis.2011.08.013
   PubMed Web of Science ®Google Scholar
• Hancock EW, Deal BJ, Mirvis DM, et al. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part V: electrocardiogram changes associated with cardiac chamber hypertrophy: a scientific statement from the American Heart Association Electrocardiography. J Am Coll Cardiol. 2009;53:992–1002. DOI:10.1016/j.jacc.2008.12.015.
   PubMed Web of Science ®Google Scholar
• Casale PN, Devereux RB, Alonso DR, et al. Improved sex-specific criteria of left ventricular hypertrophy for clinical and computer interpretation of electrocardiograms: validation with autopsy findings. Circulation. 1987;75:565–572.10.1161/01.CIR.75.3.565
   PubMed Web of Science ®Google Scholar
• Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28(1–39):e14. DOI:10.1016/j.echo.2014.10.003.
   Web of Science ®Google Scholar
• Nagueh SF, Appleton CP, Gillebert TC, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr. 2009;22:107–133. DOI:10.1016/j.echo.2008.11.023.
   PubMed Web of Science ®Google Scholar
• Gunaydin ZY, Ozer FF, Karagoz A, et al. Evaluation of cardiovascular risk in patients with Parkinson disease under levodopa treatment. J Geriatr Cardiol. 2016;13:75–80. DOI:10.11909/j.issn.1671-5411.2016.01.003.
   PubMedGoogle Scholar
• Ruhui L, Jinfa J, Jiahong X, et al. Influence of hyperhomocysteinemia on left ventricular diastolic function in Chinese patients with hypertension. Herz. 2015;40:679–684. DOI:10.1007/s00059-014-4098-x.
   PubMed Web of Science ®Google Scholar
• Kraigher-Krainer E, Shah AM, Gupta DK, et al. Impaired systolic function by strain imaging in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2014;63:447–456. DOI:10.1016/j.jacc.2013.09.052.
   PubMed Web of Science ®Google Scholar
• Maurer MS, El Khoury Rumbarger L, King DL. Ventricular volume and length in hypertensive diastolic heart failure. J Am Soc Echocardiogr. 2005;18:1051–1057. DOI:10.1016/j.echo.2005.03.003.
   PubMed Web of Science ®Google Scholar
• Friedman JH. Fatigue in Parkinson’s disease. Mov Disord. 2001;16:1120–1122.10.1002/(ISSN)1531-8257
   PubMed Web of Science ®Google Scholar
• Berganzo K, Diez-Arrola B, Tijero B, et al. Nocturnal hypertension and dysautonomia in patients with Parkinson’s disease: are they related? J Neurol. 2013;260:1752–1756. DOI:10.1007/s00415-013-6859-5.
   PubMed Web of Science ®Google Scholar
• Kim BK, Lim Y-H, Lee HT, et al. Non-dipper pattern is a determinant of the inappropriateness of left ventricular mass in essential hypertensive patients. Korean Circ J. 2011;41:191–197. DOI:10.4070/kcj.2011.41.4.191.
   PubMed Web of Science ®Google Scholar
• Tsukamoto T, Kitano Y, Kuno S. Blood pressure fluctuation and hypertension in patients with Parkinson’s disease. Brain Behav. 2013;3:710–714. DOI:10.1002/brb3.179.
   PubMed Web of Science ®Google Scholar
• Sacre JW, Franjic B, Jellis CL, et al. Association of cardiac autonomic neuropathy with subclinical myocardial dysfunction in type 2 diabetes. JACC Cardiovasc Imag. 2010;3:1207–1215. DOI:10.1016/j.jcmg.2010.09.014.
   PubMed Web of Science ®Google Scholar
• Vagaonescu TD, Saadia D, Tuhrim S, et al. Hypertensive cardiovascular damage in patients with primary autonomic failure. Lancet. 2000;355:725–726. DOI:10.1016/S0140-6736(99)05320-9.
   PubMed Web of Science ®Google Scholar
• Bhandari P, Song M, Chen Y, et al. Mitochondrial contagion induced by parkin deficiency in drosophila hearts and its containment by suppressing mitofusin. Circ Res. 2014;114:257–265. DOI:10.1161/CIRCRESAHA.114.302734.
   PubMed Web of Science ®Google Scholar
• Klawitter J, Klawitter J, Agardi E, et al. Association of DJ-1/PTEN/AKT- and ASK1/p38-mediated cell signalling with ischaemic cardiomyopathy. Cardiovasc Res. 2013;97:66–76. DOI:10.1093/cvr/cvs302.
   PubMed Web of Science ®Google Scholar
• Malik M, Andreas J-O, Hnatkova K, et al. Thorough QT/QTc study in patients with advanced parkinson’s disease: cardiac safety of rotigotine. Clin Pharmacol Ther. 2008;84:595–603. DOI:10.1038/clpt.2008.143.
   PubMed Web of Science ®Google Scholar
• Cunnington A, Hood K, White L. Outcomes of screening Parkinson’s patients for QTc prolongation. Parkinsonism Relat Disord. 2013;19:1000–1003. DOI:10.1016/j.parkreldis.2013.07.001.
   PubMed Web of Science ®Google Scholar
• Weintraub D, Chiang C, Kim HM, et al. Association of Antipsychotic Use With Mortality Risk in Patients With Parkinson Disease. JAMA Neurology. 2016;73:535–541. DOI:10.1001/jamaneurol.2016.0031.
   PubMed Web of Science ®Google Scholar
• Carabello B, Spann J. The uses and limitations of end-systolic indexes of left ventricular function. Circulation. 1984;69:1058–1064.10.1161/01.CIR.69.5.1058
   PubMed Web of Science ®Google Scholar
• Matveï A, Pasquet A, Jean A. Pramipexole-Induced Reversible Heart Failure. Mov Disord Clin Pract. 2014;1:381–382.
   PubMedGoogle Scholar
• Piercey MF, Hoffmann WE, Smith MW, et al. Inhibition of dopamine neuron firing by pramipexole, a dopamine D3 receptor-preferring agonist: comparison to other dopamine receptor agonists. Eur J Pharmacol. 1996;312:35–44.10.1016/0014-2999(96)00454-2
   PubMed Web of Science ®Google Scholar
• Pamukcu HE, Gerede DM, Sorgun M, et al. Evaluating the effect of non-ergot dopamine agonists on left ventricular systolic functions with speckle tracking echocardiography. Eur Hear J Cardiovasc Imaging Abstr Suppl. 2014;15:70.
   PubMed Web of Science ®Google Scholar